Insulin resistance pharmacology: Current situation and perspectives;Farmacología de la insulinorresistencia: Situación actual y perspectivas

Revista Argentina de Endocrinologia y Metabolismo

Volumn 41, Issue 3, 2004, Pages 159-169

  Gonzalez C D ^a   Santoro, S G ^b   Sinay, Isaac ^c,d  

^a CEMIC   (Argentina)

^b UNIVERSIDAD DEL SALVADOR   (Argentina)

^c Unidad Asistencial Dr César Milstein   (Argentina)

^d NONE   (Argentina)

Author keywords

Biguanids; Cardiovascular Risk; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 4 [3 [BIS(BETA HYDROXYPHENETHYL)AMINO]BUTYL]BENZAMIDE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; AD 9677; ADENYLATE KINASE; AZ 40140; BAY 27 9955; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BIGUANIDE DERIVATIVE; DRF 4158; FRUCTOSE BISPHOSPHATASE; GLUCAGON RECEPTOR; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 4; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE KINASE 3; GW 58418; GW 677954; INSULIN; INSULIN SENSITIZING AGENT; KT 6207; L 796568; LR 90; LY 377604; METFORMIN; MURAGLITAZAR; NAVEGLITAZAR; NNC 25 2504; NORASTERRIQUINONE B1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PYRUVATE CARBOXYLASE; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RETINOID X RECEPTOR; ROSIGLITAZONE; TESAGLITAZAR; TLK 16998; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; FATTY ACID OXIDATION; GLUCONEOGENESIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW;

EID: 4444325881     PISSN: 03264610     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Mercado, M.M.; McLenithan, J.C.; Silver, K.D. y col. Genetics of insulin resistance. Curr Diab Rep.2(1):83-95, 2002.
2. González, C. Farmacología de la Diabetes Mellitus. En: Manual de Fármacos en Cardiología. García Merletti PF, González C, Zambrano C. Akadia Ed., Buenos Aires, pag, 219,2003
3. Laborde, E.; Manchem, V.P. Small molecule activators of the insulin receptor: potential new therapeutic agents for the treatment of diabetes mellitus. Curr Med Chem. 9 (24):2231-42, 2002.
4. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 15; 348 Pt 3:607-14, 2000.
5. Leverve, X.M.; Guigas, B.; Detaille, D. y col. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. 29 (4 Pt 2):6S88-94, 2003.
6. Fryer, L.G.; Parbu-Patel, A.; Carling, D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 12;277(28):25226-32, 2002.
7. Musi, N.; Hirshman, M.F.; Nygren, J. y col. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51(7):2074-81, 2002.
8. Hawley, S.A.; Gadalla, A.E.; Olsen, G.S. y col. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51(8):2420-5, 2002.
9. Despres, J.P. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab., 29(4 Pt 2):6S53-61, 2003.
10. Luchetti, C.; Sander, V.; Gutierrez, M. y col. Efectos de una biguanida en un modelo murino de síndrome del ovario poliquístico. Medicina (Buenos Aires) 63, 5/2: 548, 2003
11. Petersen, K.E; Sullivan, J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 44(11):2018-24, 2001.
12. Madsen, P.; Ling, A.; Plewe, M. y col. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6- tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem. 19;45(26):5755-75, 2002.
13. Martinez, A.; Castro, A.; Dorronsoro, I. y col. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 22(4):373-84, 2002.
14. Puigserver, P.; Spiegelman, B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev. 24(1):78-90, 2003.
15. Rosen, E.D.; Spiegelman, B.M. PPAR gamma: a nuclear regulator of metabolism, differentiation and cell growth. Journal of Biological Chemistry. 276(1):37731-37734, 2001
16. Wang, M.; Tafuri, S. Modulation of PPAR gamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem. 1;89(1):38-47, 2003.
17. Zhu, X.; Lin, Y.; Zhang, J. y col. Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells. Cell Mol Life Sci. 60(1):212-8, 2003.
18. Micromedex @ Health Care Series. Vol. 120, 2004
19. Tadayyon, M.; Smith, S.A. Insulin sensitisation in the treatment of Type 2 diabetes. Expert Opin Investig Drugs. 12(3):307-24, 2003.
20. Faul, M.M.; Grese, T.A. Selective RXR modulators for the treatment of type II diabetes. Curr Opin Drug Discov Devel. 5(6):974-85, 2002.
21. Liu, G.; Trevillyan, J.M. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes. Curr Opin Investig Drugs. 3(11):1608-16, 2002.
22. Ljung, T.; Ottosson, M.; Ahlberg, A.C.; y col. Central and peripheral glucocorticoid receptor function in abdominal obesity. J Endocrinol Invest. 25(3):229-35, 2002.
23. Kotelevtsev, Y.; Holmes, M.C.; Burchell, A. y col. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 23;94(26):14924-9, 1997.
24. Alberts, P.; Engblom, L.; Edling, N. y col. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 45(11): 1528-32, 2002.
25. Walker, B.R.; Connacher, A.A.; Lindsay, R.M. y col. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 80(11):3155-9, 1995.
26. Knowler, W.; Barrett-Connor, E.; Fowler, S. y col. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 346:393-403, 2002.
27. Pyörälä, M.; Miettinen, H.; Laakso, M. y col. Hyperinsulinemia Predicts Coronary Heart Disease Risk in Healthy Middle-aged Men: The 22-Year Follow-up Results of the Helsinki Policemen Study. Circulation 98: 398-404, 1998.
28. Alexander, C.; Landsman, P.; Teutsch, S. y col. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older. Diabetes, 52: 1210-1214, 2003.